Related Experiment Videos
Haloperidol for agitation in dementia.
E Lonergan1, J Luxenberg, J Colford
1Department of Medicine, UCSF School of Medicine, VA Medical Center, 4150 Clement St, San Francisco, California 94121, USA. tedlnrgn@aol.com
The Cochrane Database of Systematic Reviews
|June 22, 2002
Summary
Haloperidol may help control aggression in agitated dementia patients but does not improve overall agitation. Routine use is not supported due to potential side effects and lack of broad efficacy.
Area of Science:
- Geriatric Medicine
- Psychopharmacology
- Clinical Trials
Background:
- Agitation affects up to 70% of dementia patients.
- Haloperidol has been a long-standing treatment for agitation in dementia, but its efficacy is debated.
- Previous reviews had limitations, necessitating a broader analysis.
Purpose of the Study:
- To evaluate the evidence supporting the use of haloperidol for agitation in dementia patients.
- To determine if haloperidol offers significant benefits over placebo in managing agitation.
- To assess the safety and tolerability of haloperidol in this population.
Main Methods:
- Conducted a systematic review of randomized, placebo-controlled trials.
- Searched multiple medical databases including MEDLINE, EMBASE, PsycInfo, and CINAHL.
- Included trials with concealed allocation and assessed dementia and agitation using standardized measures.
Main Results:
- Haloperidol did not show significant improvement in overall agitation compared to placebo.
- A decrease in aggression was observed in the haloperidol group.
- No significant difference in dropout rates due to adverse effects was found between haloperidol and placebo groups.
Conclusions:
- Haloperidol may be effective for aggression but not other agitation symptoms in dementia.
- Routine use of haloperidol for agitated dementia is not supported by current evidence.
- Individualized treatment and monitoring for side effects are crucial when considering haloperidol for agitated dementia.